Allan Camaisa sold $1,237 of CLDI
CEO and Chairman of the Board at Calidi Biotherapeutics, Inc.. 850 shares at an average of $1.46, traded Dec 12, 2025, filed Dec 16, 2025.
Score components
- +15RoleDirector
- 0Trade size$1k at market
- 0Share of holdings soldSold 1.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -20.0%, 3m -75.8%, 6m -87.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-25-028030, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2025 | SOpen-market sale Common Stockindirect: AJC Capital, LLC | -850 | $1.46 | $1,237 | 76,952 | Dec 16, 2025 |
Related signals
Other insiders at Calidi Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 63Notable | Calidi Biotherapeutics, Inc. | Andrew C. Jackson Chief Financial Officer | $5,000 2,500 shares | - | |
| 71Notable | Calidi Biotherapeutics, Inc. | Scott Leftwich director | $250k 125,000 shares | +2212% | |
| 73Notable | Calidi Biotherapeutics, Inc. | Eric E Poma Chief Executive Officer | $50k 25,000 shares | - | |
| 69Notable | Calidi Biotherapeutics, Inc. | James A Schoeneck director | $150k 75,000 shares | +6614% | |
| 30Weak | CLDIsell Calidi Biotherapeutics, Inc. | Allan Camaisa CEO and Chairman of the Board | $16k 10,000 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.